To analyze the clinical presentation, therapeutic intervention, and prognosis of anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis. Methods: We retrospectively analyzed the clinical data of 7 patients diagnosed with LGI1 encephalitis in our department between August 2016 and December 2018. Re? sults: Of the 7 patients, 5 were male and 2 female. The average age was 68 years old. Six patients experienced memory loss and cognitive deficits; 6 had mental and behavioral abnormalites, 2 of which experienced hallucination and 1 overeating; 4 presented faciobrachial dystonic seizures (FBDS); 5 showed sleep dysfunction; and 3 experienced seizures. All patients underwent cerebrospinal fluid examination and tested positive for LGI1 antibodies; among these, 5 patients were also positive for serum LGI1 antibodies. Four patients showed hyponatremia. Three patients presented with abnormal lesions in brain magnetic resonance imaging (MRI) located in the temporal lobe, hippocampus, and basal ganglia. Five patients exhibited abnormalities in their electroencephalograms (EEGs). No patients showed malignant tumors. All patients received first-line immunotherapy; 1 patient delayed diagnosis which resulted in poor response to treatment and recurrence. Conclusion: Anti-LGI1 encephalitis is a treatable disease and should be suspected in patients who develop rapidly progressive cognitive impairment, mental and behavioral abnormalites, FBDS, hyponatremia, and brain MRI showing lesions located mostly in the limbic system. Timely diagnosis and treatment are critical to yielding a favorable prognosis.